One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The selected official and mirror tables agree. Their CRRT guidance is explicitly initial and depends on effluent rather than a CrCl band.
What to reconcile: Confirm modality and L/hour effluent, then reassess residual function and clinical status; do not interpolate a new algorithm.
Open this note and its source referencesThe official label uses CrCl >=120; UCSF prints >120 beside 60-119. The upper effluent band is >=4.1 L/hour in the label versus >4 in UCSF.
What to reconcile: For exactly CrCl 120 the official label is explicit. Preserve the institutional discrepancy and seek clarification for effluent values between printed bands; do not interpolate. This is a wording/boundary comparison, not evidence of different clinical outcomes.
Open this note and its source referencesInfuse every dose IV over 3 hours for labeled adult cUTI/pyelonephritis or HABP/VABP.
| Cockcroft-Gault CrCl (mL/min) | Dose | Interval |
|---|---|---|
| >=120 | 2 g | Every 6 hours |
| 60-119 | 2 g | Every 8 hours |
| 30-59 | 1.5 g | Every 8 hours |
| 15-29 | 1 g | Every 8 hours |
| <15, with or without IHD | 750 mg | Every 12 hours |
Start IHD-day dosing immediately after dialysis. CRRT initial doses depend on effluent: <=2 L/hour, 1.5 g every 12 hours; 2.1-3, 2 g every 12 hours; 3.1-4, 1.5 g every 8 hours; >=4.1, 2 g every 8 hours. Clarify values between the printed decimal ranges. Reassess residual kidney function and clinical response. The label warns of increased mortality observed in a carbapenem-resistant infection trial.
RDM30-071-cefiderocol-1 · Source locator: FETROJA - adult renal and CRRT dosing; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cefiderocol&s1=RDM30-071-cefiderocol&h1=6ca7ad768286976df62c8c1fc3d0473a000aab12d4794bc18a5473084420dd9a